Table 2.
Urinary excretion, plasma concentration, and fractional clearance of EGF receptor ligands in controls and in patients with autosomal dominant polycystic kidney disease at baseline, after treatment with a vasopressin V2 receptor antagonist, and 3 weeks after stopping treatment (washout)
| Variable | Controls | Patients with ADPKD | P Value | |||||
|---|---|---|---|---|---|---|---|---|
| Baseline | V2RA | Washout | Controls versus Baseline | Treatment versus Baseline | Washout versus Treatment | Washout versus Baseline | ||
| Excretion (ng/24 hr) | ||||||||
| HB-EGF | 606 (440–806) | 1421 (1158–1854) | 2399 (2090–3114) | 1400 (1083–1866) | <0.001 | <0.001 | <0.001 | 0.66 |
| EGF | 32,939 (26,049–63,420) | 11,345 (345–26,367) | 3282 (1.2–27,006) | 6206 (456–23,253) | <0.001 | 0.44 | 0.67 | 0.70 |
| TGF-α | 3.9 (1.6–6.2) | 1.9 (0.1–7.0) | 0.1 (0.1–0.2) | 1.5 (0.1–4.2) | 0.14 | 0.01 | 0.002 | 0.21 |
| Plasma concentration (pg/ml) | ||||||||
| HB-EGF | 77.2 (37.2–174.3) | 157.9 (83.1–225.9) | 149.5 (34.4–319.1) | 122.4 (40.1–379.1) | 0.04 | 0.07 | 0.64 | 0.13 |
| EGF | 63.4 (54.9–116.2) | 24.5 (22.7–33.6) | 23.9 (21.2–30.1) | 22.9 (21.0–29.2) | <0.001 | 0.58 | 0.96 | 0.39 |
| TGF-α | 2.6 (0.4–7.4) | 4.4 (1.1–11.0) | 1.9 (0.02–6.6) | 1.4 (0.02–11.4) | 0.46 | 0.007 | 0.71 | 0.05 |
| Fractional clearance (%) | ||||||||
| HB-EGF | 4.5 (2.0–9.0) | 9.7 (2.5–25.2) | 20.7 (8.8–56.2) | 15.6 (2.9–41.9) | 0.02 | <0.001 | 0.005 | 0.11 |
| EGF | 324.4 (163.0–547.7) | 305.6 (28.9–602.7) | 170.2 (0.08–791.1) | 279.7 (32.3–517.9) | 0.46 | 0.89 | 0.92 | 0.77 |
| TGF-α | 1.0 (0.1–6.4) | 0.3 (0.0–2.2) | 0.1 (0.0–4.8) | 1.4 (0.2–22.8) | 0.19 | 0.60 | 0.004 | 0.08 |
Unless otherwise noted, values are the median (interquartile range). HB-EGF, heparin-binding EGF; ADPKD, autosomal dominant polycystic kidney disease; V2RA, vasopressin V2 receptor antagonist.